Sierra Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sierra Oncology, Inc.
Frontline Success Bolsters IO ‘Backbone’ Hopes For GSK’s Jemperli
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.
Sareum’s Lead Asset Hangs In Balance As GSK Withdraws From Oncology Pact
The big pharma has returned the global commercial rights to Sareum’s lead program which GSK gained as part of its recently completed acquisition of Sierra Oncology, leaving Sareum scrambling for a new path forward.
CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
Stock Watch: Wrap Up For The Biotech Winter
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.
- Drug Delivery
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- ProNAi Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.